Intranasal delivery of lipid-based nanoparticles for the treatment of neurodegenerative diseases: advances, challenges and future perspectives [0.03%]
基于脂质的纳米颗粒鼻内给药治疗神经退行性疾病：进展、挑战与未来展望
Xavier Mulet I Piera,Rubén Del Campo-Montoya,Mar Cuadrado-Tejedor et al.
Xavier Mulet I Piera et al.
Introduction: Neurodegenerative diseases such as Parkinson's or Alzheimer's disease urgently require new therapeutic approaches. Despite significant efforts, no disease-modifying therapies targeting specific molecular pat...
Xiomara Owen,Mohammad Hejazi,Laleh Golshahi
Xiomara Owen
Introduction: Pediatric intranasal (IN) drug delivery is a promising noninvasive way of administering medication, offering a significant improvement over parenteral and oral methods. However, its effectiveness is hindered...
Non-viral mRNA cystic fibrosis therapies and their ongoing clinical trials [0.03%]
非病毒mRNA囊性纤维化疗法及其正在进行的临床试验
Nicole A Gill,Vincent Fung,Rachel VanKeulen-Miller et al.
Nicole A Gill et al.
Introduction: Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired ion transport by the CFTR protein and accumulation of...
Microfluidic-engineered polymeric nanocarriers for targeted drug delivery in liver cancer therapy: part ii recent advances [0.03%]
用于肝癌治疗的靶向给药的微流控工程聚合物纳米载体：第2部分最新进展
Aliakbar Ebrahimiverkiani,Mahboobeh Ebrahimi Varkiani,Maryam Jadid Tavaf et al.
Aliakbar Ebrahimiverkiani et al.
Introduction: Conventional drug delivery systems in cancer therapy face limitations such as poor targeting and adverse side effects. Nanoparticle-based approaches, particularly when integrated with microfluidic technology...
Microfluidic-engineered polymeric nanocarriers for targeted drug delivery in liver cancer therapy: part I principles [0.03%]
肝癌治疗中微流控工程聚类纳米载体给药：第I部分原理
Aliakbar Ebrahimiverkiani,Mahboobeh Ebrahimi Varkiani,Maryam Jadid Tavaf et al.
Aliakbar Ebrahimiverkiani et al.
Introduction: Conventional drug delivery for cancer therapy often suffer from poor targeting efficiency, limited bioavailability, and severe off-target toxicity. Nanoparticle-based approaches have emerged as transformativ...
How can we optimize the delivery of IL-2 to traumatic brain injury patients? [0.03%]
如何优化创伤性脑损伤患者的IL-2输送？
James Dooley,Adrian Liston
James Dooley
Have we finally found the ideal nucleic acid carrier with lipo-xenopeptides? [0.03%]
脂肽共载体是理想的核酸递送系统吗？
Ernst Wagner
Ernst Wagner
Challenges and strategies for nose-to-brain delivery in treating neurological disorders [0.03%]
治疗神经障碍的鼻部给药策略及挑战
Xi Li,Xiaorong Wang,Fan Tong et al.
Xi Li et al.
Introduction: The nose-to-brain route is a promising noninvasive strategy to circumvent the blood-brain barrier (BBB) and directly target the central nervous system (CNS), addressing the pivotal challenge of poor drug del...
Fda approved PFS-based autoinjectors: evolution, market trends, and development challenges [0.03%]
FDA批准的PFS基自动注射器：演变、市场趋势及开发挑战
Jeremy Guo,Yueming Sun,Duoduo Zhang et al.
Jeremy Guo et al.
Introduction: With the rapid expansion of the biopharmaceutical industry, particularly in chronic disease treatment and immunotherapies, self-injection has emerged as a preferred method for patient-administered therapies....
Targeted immunomodulation for chronic diseases through advanced delivery platforms [0.03%]
通过高级递送平台针对慢性疾病进行免疫系统调节
Mia Girela,Dia Gupta,Alessandro Grattoni et al.
Mia Girela et al.
Introduction: Controlled drug delivery systems offer a transformative approach to targeted immunomodulation, providing a strategy for managing chronic conditions ranging from autoimmune and infectious diseases to cancer. ...